{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:25:15Z","timestamp":1775082315118,"version":"3.50.1"},"reference-count":117,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["CAN 2018,419"],"award-info":[{"award-number":["CAN 2018,419"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007231","name":"Cancer Society in Stockholm","doi-asserted-by":"publisher","award":["111293"],"award-info":[{"award-number":["111293"]}],"id":[{"id":"10.13039\/501100007231","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acute graft-versus-host disease (GVHD) is a frequent and potentially life-threatening complication following allogeneic hematopoietic cell transplantation (HCT). Mesenchymal stromal cells (MSCs), rare precursors found in all body tissues, possess immunosuppressive properties and can inhibit alloreactivity both in vitro and in vivo. Two decades ago, we introduced bone marrow-derived (BM) MSCs as a novel therapy for acute GVHD. While some patients responded to BM-MSCs, the response was not universal. Commercially available BM-MSCs are now used for acute GVHD treatment in Canada, Japan, and New Zealand. The fetus is protected from the mother\u2019s immune system by the placenta, and our research found that placenta-derived decidua stromal cells (DSCs) offer a stronger immunosuppressive effect than other sources of stromal cells. Safety studies in rabbits, rats, mice, and humans have shown negligible or no side effects from BM-MSCs or DSCs. In a phase I\/II trial for severe acute GVHD, we treated 21 patients (median age, 49 years; range 1.6-72 years) with severe biopsy-proven gastrointestinal acute GVHD. The median cell dose of DSCs was 1.2 \u00d7 106 (range 0.9-2.9) cells\/kg body weight, with a median of 2 (range 1-6) infusions given 1 week apart. The cell viability of DSCs was 93% (range, 69%-100%), and the median cell passage number was 4 (range, 2-4). All patients responded, with a complete response of acute GVHD in 11 patients and partial response in 10 and 1-year survival of 81%. Randomized trials are needed to prove the superiority of DSCs compared to ruxolitinib and\/or other novel immunosuppressive therapies.<\/jats:p>","DOI":"10.1093\/stmcls\/sxae003","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:03:43Z","timestamp":1704809023000},"page":"291-300","source":"Crossref","is-referenced-by-count":10,"title":["Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease"],"prefix":"10.1093","volume":"42","author":[{"given":"Olle","family":"Ringd\u00e9n","sequence":"first","affiliation":[{"name":"Translational Cell Therapy Research (TCR), Division of Pediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet , Huddinge , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8721-0400","authenticated-orcid":false,"given":"Behnam","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Translational Cell Therapy Research (TCR), Division of Pediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet , Huddinge , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"issue":"4","key":"2024041506055673900_CIT0001","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V49.4.511.511","article-title":"One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation","volume":"49","author":"Thomas","year":"1977","journal-title":"Blood"},{"key":"2024041506055673900_CIT0002","first-page":"625","article-title":"Treatment of aplastic anemia by marrow transplantation from HLA identical siblings. Prognostic factors associated with graft versus host disease and survival","volume-title":"J Clin Invest","author":"Storb","year":"1977"},{"key":"2024041506055673900_CIT0003","first-page":"1398","article-title":"Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation","volume-title":"Lancet","author":"Hoogerbrugge","year":"1995"},{"issue":"2","key":"2024041506055673900_CIT0004","first-page":"67","article-title":"A simple method for inducing tolerance of skin homografts in mice","volume":"4","author":"Billingham","year":"1957","journal-title":"Transplant Bull."},{"key":"2024041506055673900_CIT0005","first-page":"19","article-title":"Current concepts and advances in graft-versus-host disease immunology","volume-title":"Annu Rev Immunol","author":"Hill","year":"2021"},{"key":"2024041506055673900_CIT0006","first-page":"2441","article-title":"Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis","volume-title":"J Clin Invest","author":"Ferrara","year":"2017"},{"issue":"1","key":"2024041506055673900_CIT0007","first-page":"19","article-title":"Hemorrhagic cystitis--a manifestation of graft versus host disease","volume":"2","author":"Ost","year":"1987","journal-title":"Bone Marrow Transplant"},{"key":"2024041506055673900_CIT0008","first-page":"753","article-title":"Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease","volume-title":"Bone Marrow Transplant","author":"Cooke","year":"2004"},{"key":"2024041506055673900_CIT0009","first-page":"1434","article-title":"Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R","volume-title":"Nat Med","author":"Wilhelm","year":"2010"},{"key":"2024041506055673900_CIT0010","first-page":"648","article-title":"Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage","volume-title":"Nat Med","author":"Schwab","year":"2014"},{"key":"2024041506055673900_CIT0011","first-page":"2561","article-title":"Toll-like receptor stimulation by microRNAs in acute graft-vs-host disease","volume-title":"Front Immunol","author":"Zitzer","year":"2018"},{"key":"2024041506055673900_CIT0012","first-page":"163","article-title":"Inflammatory cytokine networks in gastrointestinal tract graft vs host disease","volume-title":"Front Immunol","author":"Piper","year":"2019"},{"key":"2024041506055673900_CIT0013","first-page":"2732","article-title":"MicroRNA-146a reduces MHC-II expression via targeting JAK\/STAT signaling in dendritic cells after stem cell transplantation","volume-title":"Leukemia","author":"Stickel","year":"2017"},{"key":"2024041506055673900_CIT0014","first-page":"e109799","article-title":"Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect","volume-title":"PLoS One","author":"Choi","year":"2014"},{"issue":"2","key":"2024041506055673900_CIT0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.V71.2.293.293","article-title":"Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials","volume":"71","author":"Storb","year":"1988","journal-title":"Blood"},{"key":"2024041506055673900_CIT0016","first-page":"641","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume-title":"Biol Blood Marrow Transplant","author":"Luznik","year":"2008"},{"key":"2024041506055673900_CIT0017","first-page":"681","article-title":"Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis","volume-title":"Transplant Cell Ther.","author":"Saliba","year":"2022"},{"key":"2024041506055673900_CIT0018","first-page":"982","article-title":"Secondary treatment of acute graft-versus-host disease: a critical review","volume-title":"Biol Blood Marrow Transplant","author":"Martin","year":"2012"},{"key":"2024041506055673900_CIT0019","first-page":"e101","article-title":"Prevention and treatment of acute graft-versus-host disease in children, adolescents, and young adults","volume-title":"Biol Blood Marrow Transplant","author":"Gatza","year":"2020"},{"key":"2024041506055673900_CIT0020","first-page":"147","article-title":"Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin","volume-title":"Clin Transplant","author":"Remberger","year":"2001"},{"key":"2024041506055673900_CIT0021","first-page":"649","article-title":"Tumor necrosis factor-alpha blockade for the treatment of acute GVHD","volume-title":"Blood","author":"Couriel","year":"2004"},{"key":"2024041506055673900_CIT0022","first-page":"45","article-title":"Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation","volume-title":"Am J Hematol","author":"Busca","year":"2007"},{"issue":"3","key":"2024041506055673900_CIT0023","first-page":"405","article-title":"The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease","volume":"91","author":"Greinix","year":"2006","journal-title":"Haematologica"},{"key":"2024041506055673900_CIT0024","first-page":"609","article-title":"Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD","volume-title":"Bone Marrow Transplant","author":"Perfetti","year":"2008"},{"key":"2024041506055673900_CIT0025","first-page":"220","article-title":"Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation","volume-title":"Eur J Haematol","author":"Forslow","year":"2012"},{"key":"2024041506055673900_CIT0026","article-title":"Vedolizumab for prophylaxis of lower gastrointestinal (GI) acute graft-versus-host disease (aGvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) from unrelated donors: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study (GRAPHITE)","author":"Yi-Bin Chen"},{"key":"2024041506055673900_CIT0027","first-page":"1800","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume-title":"N Engl J Med","author":"Zeiser","year":"2020"},{"key":"2024041506055673900_CIT0028","first-page":"1739","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume-title":"Blood","author":"Jagasia","year":"2020"},{"issue":"2","key":"2024041506055673900_CIT0029","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00007890-196803000-00009","article-title":"Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues","volume":"6","author":"Friedenstein","year":"1968","journal-title":"Transplantation"},{"key":"2024041506055673900_CIT0030","first-page":"143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume-title":"Science","author":"Pittenger","year":"1999"},{"issue":"7","key":"2024041506055673900_CIT0031","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1634\/stemcells.2004-0058","article-title":"Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta","volume":"22","author":"In \u2018t Anker","year":"2004","journal-title":"Stem Cells"},{"key":"2024041506055673900_CIT0032","first-page":"641","article-title":"Mesenchymal stem cells","volume-title":"J Orthop Res","author":"Caplan","year":"1991"},{"key":"2024041506055673900_CIT0033","first-page":"93","article-title":"Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart","volume-title":"Circulation","author":"Toma","year":"2002"},{"key":"2024041506055673900_CIT0034","first-page":"71","article-title":"Marrow stromal cells as stem cells for nonhematopoietic tissues","volume-title":"Science","author":"Prockop","year":"1997"},{"key":"2024041506055673900_CIT0035","first-page":"890","article-title":"HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells","volume-title":"Exp Hematol","author":"Le Blanc","year":"2003"},{"key":"2024041506055673900_CIT0036","first-page":"42","article-title":"Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo","volume-title":"Exp Hematol","author":"Bartholomew","year":"2002"},{"key":"2024041506055673900_CIT0037","first-page":"11","article-title":"Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex","volume-title":"Scand J Immunol","author":"Le Blanc","year":"2003"},{"key":"2024041506055673900_CIT0038","first-page":"1815","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume-title":"Blood","author":"Aggarwal","year":"2005"},{"issue":"4","key":"2024041506055673900_CIT0039","first-page":"516","article-title":"Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory\/suppressive phenotype","volume":"90","author":"Maccario","year":"2005","journal-title":"Haematologica"},{"key":"2024041506055673900_CIT0040","first-page":"33","article-title":"Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms","volume-title":"Exp Cell Res","author":"Rasmusson","year":"2005"},{"key":"2024041506055673900_CIT0041","first-page":"42","article-title":"Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production","volume-title":"Nat Med","author":"N\u00e9meth","year":"2009"},{"key":"2024041506055673900_CIT0042","first-page":"212","article-title":"Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress t lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells","volume-title":"Stem Cells","author":"Selmani","year":"2008"},{"key":"2024041506055673900_CIT0043","first-page":"3770","article-title":"Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells","volume-title":"Blood","author":"Gieseke","year":"2010"},{"key":"2024041506055673900_CIT0044","first-page":"4619","article-title":"Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation","volume-title":"Blood","author":"Meisel","year":"2004"},{"key":"2024041506055673900_CIT0045","first-page":"1191","article-title":"Prevention of allogeneic fetal rejection by tryptophan catabolism","volume-title":"Science","author":"Munn","year":"1998"},{"key":"2024041506055673900_CIT0046","first-page":"1482","article-title":"Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway","volume-title":"Eur J Immunol","author":"Augello","year":"2005"},{"key":"2024041506055673900_CIT0047","first-page":"2321","article-title":"Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression","volume-title":"J Immunol","author":"Ren","year":"2010"},{"key":"2024041506055673900_CIT0048","first-page":"544","article-title":"Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-\/FAS-mediated T cell apoptosis","volume-title":"Cell Stem Cell.","author":"Akiyama","year":"2012"},{"key":"2024041506055673900_CIT0049","first-page":"66","article-title":"Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes","volume-title":"Stem Cell Res","author":"Saldanha-Araujo","year":"2011"},{"key":"2024041506055673900_CIT0050","first-page":"141","article-title":"Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide","volume-title":"Cell Stem Cell.","author":"Ren","year":"2008"},{"key":"2024041506055673900_CIT0051","first-page":"eaam7828","article-title":"Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation","volume-title":"Sci Transl Med","author":"Galleu","year":"2017"},{"key":"2024041506055673900_CIT0052","first-page":"6495","article-title":"Mesenchymal stromal cell apoptosis is required for their therapeutic function","volume-title":"Nat Commun","author":"Pang","year":"2021"},{"key":"2024041506055673900_CIT0053","first-page":"602","article-title":"Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells","volume-title":"Stem Cells","author":"de Witte","year":"2018"},{"key":"2024041506055673900_CIT0054","first-page":"4057","article-title":"Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice","volume-title":"Blood","author":"Eliopoulos","year":"2005"},{"key":"2024041506055673900_CIT0055","first-page":"711","article-title":"Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons","volume-title":"Cell Transplant","author":"Beggs","year":"2006"},{"key":"2024041506055673900_CIT0056","first-page":"1208","article-title":"No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients","volume-title":"Haematologica","author":"Sundin","year":"2007"},{"key":"2024041506055673900_CIT0057","first-page":"e21703","article-title":"Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses","volume-title":"PLoS One","author":"Moll","year":"2011"},{"key":"2024041506055673900_CIT0058","first-page":"3436","article-title":"Mesenchymal stem cells are injured by complement after their contact with serum","volume-title":"Blood","author":"Li","year":"2012"},{"key":"2024041506055673900_CIT0059","first-page":"1565","article-title":"Are therapeutic human mesenchymal stromal cells compatible with human blood","volume-title":"Stem Cells","author":"Moll","year":"2012"},{"key":"2024041506055673900_CIT0060","first-page":"149","article-title":"Intravascular mesenchymal stromal\/stem cell therapy product diversification: time for new clinical guidelines","volume-title":"Trends Mol Med","author":"Moll","year":"2019"},{"key":"2024041506055673900_CIT0061","first-page":"307","article-title":"Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy","volume-title":"J Clin Oncol","author":"Ko\u00e7","year":"2000"},{"key":"2024041506055673900_CIT0062","first-page":"1390","article-title":"Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease","volume-title":"Transplantation","author":"Ringden","year":"2006"},{"key":"2024041506055673900_CIT0063","first-page":"1579","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume-title":"Lancet","author":"Le Blanc","year":"2008"},{"key":"2024041506055673900_CIT0064","volume-title":"Mesenchymal Stem Cell Therapy","author":"Ringd\u00e9n","year":"2013"},{"key":"2024041506055673900_CIT0065","first-page":"835","article-title":"A Phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease","volume-title":"Biol Blood Marrow Transplant","author":"Kebriaei","year":"2020"},{"key":"2024041506055673900_CIT0066","first-page":"501","article-title":"Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease","volume-title":"Br J Haematol","author":"Ball","year":"2013"},{"key":"2024041506055673900_CIT0067","first-page":"859","article-title":"Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III\/IV after hematopoietic stem cell transplantation","volume-title":"Bone Marrow Transplant","author":"Dotoli","year":"2017"},{"key":"2024041506055673900_CIT0068","first-page":"606","article-title":"Good responses but high TRM in adult patients after MSC therapy for GvHD","volume-title":"Bone Marrow Transplant","author":"Salmenniemi","year":"2017"},{"key":"2024041506055673900_CIT0069","first-page":"e45","article-title":"Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis","volume-title":"Lancet Haematol.","author":"Hashmi","year":"2016"},{"key":"2024041506055673900_CIT0070","first-page":"CD009768","article-title":"Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition","volume-title":"Cochrane Database Syst Rev","author":"Fisher","year":"2019"},{"key":"2024041506055673900_CIT0071","first-page":"1577","article-title":"Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation \u201cMSC-FFM\u201d-outcome report of 92 patients","volume-title":"Cells.","author":"Bonig","year":"2019"},{"key":"2024041506055673900_CIT0072","first-page":"1641402","article-title":"Mesenchymal stem cell treatment for steroid refractory graft-versus-host disease in children: a pilot and first study from Turkey","volume-title":"Stem Cells Int.","author":"Erbey","year":"2016"},{"key":"2024041506055673900_CIT0073","first-page":"357","article-title":"Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome","volume-title":"Stem Cells","author":"von Dalowski","year":"2016"},{"key":"2024041506055673900_CIT0074","first-page":"855","article-title":"Study 275: updated expanded access program for remestemcel-l in steroid-refractory acute graft-versus-host disease in children","volume-title":"Biol Blood Marrow Transplant","author":"Kurtzberg","year":"2020"},{"key":"2024041506055673900_CIT0075","first-page":"2869","article-title":"Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers","volume-title":"Bone Marrow Transplant","author":"Kasikis","year":"2021"},{"key":"2024041506055673900_CIT0076","first-page":"619","article-title":"Comparison of mesenchymal stromal cells from different origins for the treatment of graft-vs-host-disease in a humanized mouse model","volume-title":"Front Immunol","author":"Gr\u00e9goire","year":"2019"},{"key":"2024041506055673900_CIT0077","first-page":"907","article-title":"The role of allogenic amniotic membrane in burn treatment","volume-title":"J Burn Care Res","author":"Kesting","year":"2008"},{"key":"2024041506055673900_CIT0078","first-page":"571","article-title":"Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials","volume-title":"Br J Haematol","author":"Brooke","year":"2009"},{"key":"2024041506055673900_CIT0079","first-page":"300","article-title":"Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells","volume-title":"Stem Cells","author":"Parolini","year":"2008"},{"key":"2024041506055673900_CIT0080","first-page":"543","article-title":"Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro","volume-title":"Clin Exp Immunol","author":"Karlsson","year":"2012"},{"key":"2024041506055673900_CIT0081","first-page":"2596","article-title":"Decidual stromal cells promote regulatory T cells and suppress alloreactivity in a cell contact-dependent manner","volume-title":"Stem Cells Dev","author":"Erkers","year":"2013"},{"key":"2024041506055673900_CIT0082","first-page":"253","article-title":"Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling","volume-title":"Stem Cells Dev","author":"Erkers","year":"2015"},{"key":"2024041506055673900_CIT0083","first-page":"2269","article-title":"Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua","volume-title":"Stem Cells Dev","author":"Moll","year":"2015"},{"key":"2024041506055673900_CIT0084","first-page":"1550","article-title":"Graft-versus-host disease","volume-title":"Lancet","author":"Ferrara","year":"2009"},{"key":"2024041506055673900_CIT0085","first-page":"592","article-title":"Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease","volume-title":"Stem Cells","author":"Ringd\u00e9n","year":"2013"},{"key":"2024041506055673900_CIT0086","first-page":"100249","article-title":"Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis","volume-title":"EClinicalMedicine.","author":"Thompson","year":"2020"},{"key":"2024041506055673900_CIT0087","first-page":"e47559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume-title":"PLoS One","author":"Lalu","year":"2012"},{"key":"2024041506055673900_CIT0088","first-page":"545","article-title":"The safety of MSC therapy over the past 15 years: a meta-analysis","volume-title":"Stem Cell Res Ther","author":"Wang","year":"2021"},{"key":"2024041506055673900_CIT0089","first-page":"401","article-title":"Intra-arterial administration of placenta-derived decidual stromal cells to the superior mesenteric artery in the rabbit: distribution of cells, feasibility, and safety","volume-title":"Cell Transplant","author":"Arnberg","year":"2016"},{"key":"2024041506055673900_CIT0090","first-page":"2685","article-title":"Preclinical toxicity evaluation of clinical grade placenta-derived decidua stromal cells","volume-title":"Front Immunol","author":"Sadeghi","year":"2019"},{"key":"2024041506055673900_CIT0091","first-page":"795","article-title":"Safety and side effects of using placenta-derived decidual stromal cells for graft-versus-host disease and hemorrhagic cystitis","volume-title":"Front Immunol","author":"Baygan","year":"2017"},{"key":"2024041506055673900_CIT0092","first-page":"325","article-title":"Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease","volume-title":"Stem Cells Transl Med.","author":"Ringden","year":"2018"},{"issue":"10","key":"2024041506055673900_CIT0093","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.bbmt.2019.05.034","article-title":"Long-term follow-up of a pilot study using placenta-derived decidua stromal cells for severe acute graft-versus-host disease","volume":"25","author":"Sadeghi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024041506055673900_CIT0094","first-page":"945","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume-title":"Biol Blood Marrow Transplant","author":"Filipovich","year":"2005"},{"key":"2024041506055673900_CIT0095","first-page":"2365","article-title":"Manufacturing mesenchymal stromal cells for the treatment of graft-versus-host disease: a survey among centers affiliated with the European society for blood and marrow transplantation","volume-title":"Biol Blood Marrow Transplant","author":"Trento","year":"2018"},{"key":"2024041506055673900_CIT0096","first-page":"812","article-title":"MSCs: science and trials","volume-title":"Nat Med","author":"Phinney","year":"2013"},{"issue":"6","key":"2024041506055673900_CIT0097","first-page":"635","article-title":"Variables predicting deep fungal infections in bone marrow transplant recipients","volume":"4","author":"Tollemar","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"2024041506055673900_CIT0098","first-page":"822","article-title":"Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients","volume-title":"Int J Hematol","author":"Remberger","year":"2012"},{"key":"2024041506055673900_CIT0099","first-page":"1068","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts","volume-title":"N Engl J Med","author":"Weiden","year":"1979"},{"issue":"3","key":"2024041506055673900_CIT0100","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"2024041506055673900_CIT0101","first-page":"614","article-title":"The allogeneic graft-versus-cancer effect","volume-title":"Br J Haematol","author":"Ringden","year":"2009"},{"key":"2024041506055673900_CIT0102","first-page":"166","article-title":"What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease","volume-title":"J Intern Med","author":"Ringden","year":"2018"},{"key":"2024041506055673900_CIT0103","first-page":"897","article-title":"Solid cancers after bone marrow transplantation","volume-title":"N Engl J Med","author":"Curtis","year":"1997"},{"key":"2024041506055673900_CIT0104","first-page":"753","article-title":"Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study","volume-title":"Immunotherapy","author":"Barkholt","year":"2009"},{"key":"2024041506055673900_CIT0105","first-page":"131","article-title":"Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies","volume-title":"Stem Cell Res Ther","author":"Noronha","year":"2019"},{"key":"2024041506055673900_CIT0106","first-page":"2429","article-title":"Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFN\u03b3 licensing","volume-title":"Stem Cells","author":"Chinnadurai","year":"2016"},{"key":"2024041506055673900_CIT0107","first-page":"1549","article-title":"Pretreatment with interferon-\u03b3 enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis","volume-title":"Stem Cells","author":"Duijvestein","year":"2011"},{"key":"2024041506055673900_CIT0108","first-page":"147","article-title":"Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-\u03b3 licensing","volume-title":"Cytotherapy","author":"Fran\u00e7ois","year":"2012"},{"key":"2024041506055673900_CIT0109","first-page":"2430","article-title":"Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties","volume-title":"Stem Cells","author":"Moll","year":"2014"},{"key":"2024041506055673900_CIT0110","first-page":"586","article-title":"Effects of freeze-thawing and intravenous infusion on mesenchymal stromal cell gene expression","volume-title":"Stem Cells Dev","author":"Hoogduijn","year":"2016"},{"key":"2024041506055673900_CIT0111","first-page":"68","article-title":"Immunomodulation by placenta-derived decidua stromal cells role of histocompatibility, accessory cells and freeze-thawing","volume-title":"Cytotherapy","author":"Sadeghi","year":"2023"},{"key":"2024041506055673900_CIT0112","first-page":"2271","article-title":"Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon","volume-title":"Leukemia","author":"Ringden","year":"2007"},{"key":"2024041506055673900_CIT0113","first-page":"463","article-title":"Stem cell therapy for Crohn\u2019s disease: systematic review and meta-analysis of preclinical and clinical studies","volume-title":"Stem Cell Res Ther","author":"Wang","year":"2021"},{"key":"2024041506055673900_CIT0114","first-page":"839844","article-title":"Mesenchymal stromal cells for enhancing hematopoietic engraftment and treatment of graft-versus-host disease, hemorrhages and acute respiratory distress syndrome","volume-title":"Front Immunol","author":"Ringd\u00e9n","year":"2022"},{"key":"2024041506055673900_CIT0115","first-page":"10554","article-title":"Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells","volume-title":"J Cell Mol Med","author":"Sadeghi","year":"2021"},{"key":"2024041506055673900_CIT0116","first-page":"106","article-title":"Placenta-derived decidua stromal cells for hemorrhagic cystitis after stem cell transplantation","volume-title":"Acta Haematol","author":"Aronsson-Kurttila","year":"2018"},{"issue":"4","key":"2024041506055673900_CIT0117","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12185-019-02804-w","article-title":"Treatment of radiculomyelopathy in two patients with placenta-derived decidua stromal cells","volume":"111","author":"Sadeghi","year":"2020","journal-title":"Int J Hematol"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stmcls\/advance-article-pdf\/doi\/10.1093\/stmcls\/sxae003\/56279558\/sxae003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/42\/4\/291\/57189690\/sxae003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/42\/4\/291\/57189690\/sxae003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T06:06:57Z","timestamp":1713161217000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/42\/4\/291\/7515029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":117,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,1,10]]},"published-print":{"date-parts":[[2024,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/stmcls\/sxae003","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2024,1,10]]}}}